Abstract
Necroptosis represents a form of programmed cell death that can be engaged by various upstream signals, for example by ligation of death receptors, by viral sensors or by pattern recognition receptors. It depends on several key signaling proteins, including the kinases Receptor-Interacting Protein (RIP)1 and RIP3 and the pseudokinase mixed-lineage kinase domain-like protein (MLKL). Necroptosis has been implicated in a number of physiological and pathophysiological conditions and is disturbed in many human diseases. Thus, targeted interference with necroptosis signaling may offer new opportunities for the treatment of human diseases. Besides structure-based drug design, in recent years drug repositioning has emerged as a promising alternative to develop drug-like compounds. There is accumulating evidence showing that multi-targeting kinase inhibitors, for example Dabrafenib, Vemurafenib, Sorafenib, Pazopanib and Ponatinib, used for the treatment of cancer also display anti-necroptotic activity. This review summarizes recent evidence indicating that some anticancer kinase inhibitors also negatively affect necroptosis signaling. This implies that some cancer therapeutics may be repurposed for other pathologies, e.g. ischemic or in...Continue Reading
References
Aug 3, 2004·Nature Reviews. Drug Discovery·Ted T Ashburn, Karl B Thor
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley
Nov 23, 2007·Journal of Cellular and Molecular Medicine·Richard A Lockshin, Zahra Zakeri
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Herbert I HurwitzLini Pandite
Nov 3, 2009·Cancer Cell·Thomas O'HareTim Clackson
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E HutsonRobert A Figlin
Sep 9, 2010·Nature Reviews. Molecular Cell Biology·Peter VandenabeeleGuido Kroemer
Nov 10, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James E Ward, Walter M Stadler
Dec 2, 2010·Chemical Biology & Drug Design·Tianjun ZhouXiaotian Zhu
May 19, 2012·Lancet·Winette T A van der GraafUNKNOWN PALETTE study group
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz
Mar 12, 2013·Structure·Tian XieYigong Shi
Sep 14, 2013·Cell Death & Disease·L SteinhartS Fulda
Jan 24, 2014·Nature Reviews. Molecular Cell Biology·Tom Vanden BerghePeter Vandenabeele
Jan 31, 2014·The New England Journal of Medicine·Andreas Linkermann, Douglas R Green
Feb 19, 2014·The Journal of Cell Biology·Sho MoriokaJun Ninomiya-Tsuji
Feb 22, 2014·Science·Kim NewtonVishva M Dixit
Jun 6, 2014·Cell Death & Disease·J-X LiZ-H Miao
Jun 6, 2014·Nature Medicine·Stephen M Strittmatter
Sep 23, 2014·Cell Death and Differentiation·L GalluzziG Kroemer
Dec 3, 2014·Molecular Cell·Pratyusha MandalWilliam J Kaiser
Mar 25, 2015·Cell Reports·Malek NajjarAlexei Degterev
May 23, 2015·Cell Death & Disease·A FausterG Superti-Furga
Jun 2, 2015·Cancer Letters·Sofie SteinwascherSimone Fulda
Nov 10, 2015·The Lancet Oncology·Naval Daver, Marina Konopleva
Apr 7, 2016·Cellular and Molecular Life Sciences : CMLS·Alexei Degterev, Andreas Linkermann
Nov 12, 2016·Cell Death and Differentiation·Katharina RohdeSimone Fulda
Jul 1, 2017·Cell Death & Disease·Sofie MartensPeter Vandenabeele
Oct 6, 2017·Oncotarget·Friederike FeldmannSimone Fulda
Citations
Jun 4, 2020·The Journal of Infectious Diseases·Sarah M BenoCarlos J Orihuela
Dec 11, 2019·Cells·Takehiro SugayaEiji Itoi
Aug 9, 2020·Cancers·Sheng-Kai HsuChien-Chih Chiu
Feb 20, 2021·Cell Death & Disease·Martina RaudenskáMichal Masařík
Jun 3, 2021·Cancers·Radka MichalkovaJan Mojzis
Nov 12, 2021·Aging Cell·Sabira MohammedSathyaseelan S Deepa
Nov 30, 2021·Basic & Clinical Pharmacology & Toxicology·Qi ZhaoLijun Yang